AndhraNews.net
Home » Business News » 2014 » November » November 19, 2014

Medifocus Inc.'s Form 20-F Registration Statement Becomes Effective Immediately


November 19, 2014 - Columbia, Md And Toronto, ON

Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that its Registration Statement on Form 20-F that was filed with the U.S. Securities and Exchange Commission (the "SEC") on September 17, 2014, as subsequently amended, has now become effective. As a result, Medifocus' common shares are now registered with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

As a result of the registration statement becoming effective, Medifocus is now an SEC-reporting foreign private issuer, and is obligated to file certain reports under the Exchange Act, including Annual Reports on Form 20-F, Reports of Foreign Private Issuers on Form 6-K, and other reports applicable to foreign private issuers. The Company's Registration Statement on Form 20-F, as amended, has been filed with the SEC and is available online at http://www.sec.gov/cgi-bin/browse-edgar?company=Medifocus+Inc&owner=exclude&action=getcompany

"We are extremely pleased that this registration statement is now effective. This is an important step in our longer term goal to move onto a listed exchange with larger capital markets," said Dr. Augustine Cheung, President and CEO of Medifocus. "We will evaluate all our options in the near future in our efforts to broaden our investor base and trading liquidity."

About Medifocus Inc.

Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drugs Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers. Please visit www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.

Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect the structure and the proceeds of the Offering and the expected use of the proceeds. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, Medifocus disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Medifocus Contact:
John Mon
COO
Medifocus, Inc.
Tel: 410-290-5734
JohnMon@medifocusinc.com

MarketWire

Comment on this story

Share